We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

NIH Launches Human RSV Study

News   Aug 27, 2015

 
NIH Launches Human RSV Study
 
 
Advertisement
 

RELATED ARTICLES

Oxford–AstraZeneca COVID-19 Vaccine: Regulators Give Update on Links to Rare Clotting Disorders

News

Dual announcements from regulators in the EU and the UK have jointly concluded that the Oxford–AstraZeneca vaccine, now trademarked as Vaxzevria, is effective at preventing COVID-19 and, overall, has benefits that outweigh any risk posed by extremely rare clotting disorders linked to the vaccine.

READ MORE

First Images of Cells Exposed to COVID-19 Vaccine

News

New research has for the first time compared images of the protein spikes that develop on the surface of cells exposed to the Oxford-AstraZeneca vaccine to the protein spike of the SARS-CoV-19 coronavirus.

READ MORE

Phase 1 Study of Novel Oral Antiviral Against SARS-CoV-2 Initiated

News

Pfizer's oral antiviral clinical candidate PF-07321332, a SARS-CoV2-3CL protease inhibitor, is progressing to Phase 1 testing following preclinical testing demonstrating potent in vitro anti-viral activity against SARS-CoV-2.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE